General Information:

Id: 906 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
SirT1 ASO: knockdown of SirT1 expression in liver and adipose tissue, diabetic via initial streptozotocin injection and 4 weeks of fructose- and high-fat-feeding
Reference: Erion DM et al.(2009) SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc. Natl. Acad. Sci. U.S.A. 106 [PMID: 19549853]

Interaction Information:

Comment SirT1 ASO reduced total plasma cholesterol 29%, which could be attributed to a 33% reduction in HDL cholesterol. Cyp7A1 is a target of LXRalpha, so it is unclear why Cyp7A1 is up-regulated in the SirT1 ASO group. However, this result could explain why SirT1 ASO reduces plasma cholesterol in this rodent model of T2DM.
Formal Description
Interaction-ID: 5449



affects_quantity of

drug/chemical compound


in blood; if SIRT1 is knocked down in liver and adipose tissue of diabetic rats
Drugbank entries Show/Hide entries for